Robert S Brown1, Maria Buti2, Lino Rodrigues3, Vladimir Chulanov4, Wan-Long Chuang5, Humberto Aguilar6, Gábor Horváth7, Elimelech Zuckerman8, Barbara Rosado Carrion9, Federico Rodriguez-Perez10, Petr Urbánek11, Armand Abergel12, Eric Cohen3, Sandra S Lovell3, Gretja Schnell3, Chih-Wei Lin3, Jiuhong Zha3, Stanley Wang3, Roger Trinh3, Federico J Mensa3, Margaret Burroughs3, Franco Felizarta13. 1. Weill Cornell Medical College, Center for Liver Disease and Transplantation, New York, NY, USA. Electronic address: rsb2005@med.cornell.edu. 2. Vall d'Hebron University Hospital and CiBERHED del Instituto Carlos III, Barcelona, Spain. 3. AbbVie Inc., North Chicago, IL, USA. 4. Central Research Institute of Epidemiology, Reference Center for Viral Hepatitis, Moscow, Russia; Sechenov First Moscow State Medical University, Moscow, Russia. 5. Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 6. Louisiana Research Center, Shreveport, LA, USA. 7. Hepatology Center of Buda, Budapest, Hungary. 8. Liver Unit, Carmel Medical Center, Faculty of Medicine, Technion Institute, Haifa, Israel. 9. Director of GHGCPR Research Institute, Ponce, Puerto Rico. 10. Klinical Investigations Group, San Juan, Puerto Rico. 11. Charles University and Central Military Hospital, Prague, Czech Republic. 12. CHU Estaing University Hospital, Clermont-Ferrand, France. 13. Private Practice, Bakersfield, CA, USA.
Abstract
BACKGROUND & AIMS: Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated glecaprevir/pibrentasvir once daily for 8 weeks in treatment-naïve patients with compensated cirrhosis. METHODS: EXPEDITION-8 was a single-arm, multicenter, phase IIIb trial. The primary and key secondary efficacy analyses were to compare the lower bound of the 95% CI of the SVR12 rate in i) patients with GT1,2,4-6 in the per protocol (PP) population, ii) patients with GT1,2,4-6 in the intention-to-treat (ITT) population, iii) patients with GT1-6 in the PP population, and iv) patients with GT1-6 in the ITT population, to pre-defined efficacy thresholds based on historical SVR12 rates for 12 weeks of glecaprevir/pibrentasvir in the same populations. Safety was also assessed. RESULTS: A total of 343 patients were enrolled. Most patients were male (63%), white (83%), and had GT1 (67%). The SVR12 rate in patients with GT1-6 was 99.7% (n/N = 334/335; 95%CI 98.3-99.9) in the PP population and 97.7% (n/N = 335/343; 95% CI 96.1-99.3) in the ITT population. All primary and key secondary efficacy analyses were achieved. One patient (GT3a) experienced relapse (0.3%) at post-treatment week 4. Common adverse events (≥5%) were fatigue (9%), pruritus (8%), headache (8%), and nausea (6%). Serious adverse events (none related) occurred in 2% of patients. No adverse event led to study drug discontinuation. Clinically significant laboratory abnormalities were infrequent. CONCLUSIONS: Eight-week glecaprevir/pibrentasvir was well tolerated and led to a similarly high SVR12 rate as the 12-week regimen in treatment-naïve patients with chronic HCV GT1-6 infection and compensated cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03089944. LAY SUMMARY: This study was the first to evaluate an 8-week direct-acting antiviral (DAA) regimen active against all major types of hepatitis C virus (HCV) in untreated patients with compensated cirrhosis. High virological cure rates were achieved with glecaprevir/pibrentasvir across HCV genotypes 1-6, and these high cure rates did not depend on any patient or viral characteristics present before treatment. This may simplify care and allow non-specialist healthcare professionals to treat these patients, contributing to global efforts to eliminate HCV.
BACKGROUND & AIMS: Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated glecaprevir/pibrentasvir once daily for 8 weeks in treatment-naïve patients with compensated cirrhosis. METHODS: EXPEDITION-8 was a single-arm, multicenter, phase IIIb trial. The primary and key secondary efficacy analyses were to compare the lower bound of the 95% CI of the SVR12 rate in i) patients with GT1,2,4-6 in the per protocol (PP) population, ii) patients with GT1,2,4-6 in the intention-to-treat (ITT) population, iii) patients with GT1-6 in the PP population, and iv) patients with GT1-6 in the ITT population, to pre-defined efficacy thresholds based on historical SVR12 rates for 12 weeks of glecaprevir/pibrentasvir in the same populations. Safety was also assessed. RESULTS: A total of 343 patients were enrolled. Most patients were male (63%), white (83%), and had GT1 (67%). The SVR12 rate in patients with GT1-6 was 99.7% (n/N = 334/335; 95%CI 98.3-99.9) in the PP population and 97.7% (n/N = 335/343; 95% CI 96.1-99.3) in the ITT population. All primary and key secondary efficacy analyses were achieved. One patient (GT3a) experienced relapse (0.3%) at post-treatment week 4. Common adverse events (≥5%) were fatigue (9%), pruritus (8%), headache (8%), and nausea (6%). Serious adverse events (none related) occurred in 2% of patients. No adverse event led to study drug discontinuation. Clinically significant laboratory abnormalities were infrequent. CONCLUSIONS: Eight-week glecaprevir/pibrentasvir was well tolerated and led to a similarly high SVR12 rate as the 12-week regimen in treatment-naïve patients with chronic HCV GT1-6 infection and compensated cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03089944. LAY SUMMARY: This study was the first to evaluate an 8-week direct-acting antiviral (DAA) regimen active against all major types of hepatitis C virus (HCV) in untreated patients with compensated cirrhosis. High virological cure rates were achieved with glecaprevir/pibrentasvir across HCV genotypes 1-6, and these high cure rates did not depend on any patient or viral characteristics present before treatment. This may simplify care and allow non-specialist healthcare professionals to treat these patients, contributing to global efforts to eliminate HCV.
Authors: Jesse Powell; Margaret Ricco; Jessica Naugle; Catherine Magee; Hayat Hassan; Carmen Masson; Grace Braimoh; Barry Zevin; Mandana Khalili Journal: Open Forum Infect Dis Date: 2021-09-25 Impact factor: 3.835
Authors: Edward Gane; Victor de Ledinghen; Douglas E Dylla; Giuliano Rizzardini; Mitchell L Shiffman; Stephen T Barclay; Jose Luis Calleja; Zhenyi Xue; Margaret Burroughs; Julio A Gutierrez Journal: J Viral Hepat Date: 2021-09-08 Impact factor: 3.517
Authors: Markus Cornberg; Adriana Ahumada; Alessio Aghemo; Massimo Andreoni; Abhi Bhagat; Isabel Butrymowicz; Michal Carmiel; Gabriel Chodick; Brian Conway; Yanna Song; Antonio Gasbarrini; Dietrich Hüppe; Francisco Jorquera Plaza; Pietro Lampertico; Maria Luisa Manzano Alonso; Lindsay Myles; Marcello Persico; Alnoor Ramji; Christoph Sarrazin; Erica Villa; Clara Weil; Juan Isidro Uriz Otano Journal: Adv Ther Date: 2022-05-11 Impact factor: 4.070
Authors: Xavier Forns; Jordan J Feld; Douglas E Dylla; Stanislas Pol; Kazuaki Chayama; Jinlin Hou; Jeong Heo; Pietro Lampertico; Ashley Brown; Mark Bondin; Fernando Tatsch; Margaret Burroughs; John Marcinak; Zhenzhen Zhang; Amanda Emmett; Stuart C Gordon; Ira M Jacobson Journal: Adv Ther Date: 2021-05-22 Impact factor: 3.845
Authors: Eleanor Barnes; Michael Pavlides; Arjun N A Jayaswal; Christina Levick; Jane Collier; Elizabeth M Tunnicliffe; Matthew D Kelly; Stefan Neubauer Journal: Abdom Radiol (NY) Date: 2020-11-28
Authors: Young Joo Park; Hyun Young Woo; Jeong Heo; Sang Gyu Park; Young Mi Hong; Ki Tae Yoon; Dong Uk Kim; Gwang Ha Kim; Hyung Hoi Kim; Geun Am Song; Mong Cho Journal: Gut Liver Date: 2021-05-15 Impact factor: 4.519